You are here

  • Home
  • Archive
  • Volume 72, Issue 2
  • One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare

Article Text

Article menu
Download PDFPDF
Letters
One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare

https://doi.org/10.1136/annrheumdis-2012-201926

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors I-HS: study design, project management, patient recruitment, data analysis, data interpretation, manuscript preparation. FH: patient recruitment. MR: study design, data interpretation. JL: statistical analysis. HA and JB: data interpretation. IH-R: project management. JS: study design, principal investigator, sponsor, data interpretation, manuscript preparation.

    • Funding This study was supported by an unrestricted grant from Roche.

    • Competing interests This study was supported by an unrestricted grant from Roche. IS and FH: Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals: consulting fees or other remuneration. IR: employee from Roche Pharma AG. MR, JB and JS: Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals, UCB: consulting fees or other remuneration. HA and JL: none.

    • Patient consent Obtained.

    • Ethics approval Ethics approval provided by Landesamt für Gesundheit und Soziales, Geschäftsstelle der Ethik-Kommission des Landes Berlin, Sächsische Straße 28, 10707 Berlin, Germany.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement We collected blood for cytokine analysis.